Idenfificafion of new targets and novel treatment strategies for chronic mvelold leukemia. Ralph B. Arilnahaus. Ph.D.- My laboratory has published new information on several key proteins in chronic myelogenous leukemia that are regulated by the Bcr-Abl oncoprotein. These proteins are lipocalin 2 (NGAL/24p3), Jak2 and Bcr. We were first to discover the role of lipocalin 2 in Bcr-Abl induced leukemia (Lin et al. Oncogene 2005). Our recent studies with 24p3 null mice showed that 24p3 secretion by Bcr-Abl+ cells is a requirement for leukemia inducfion by Bcr-Abl in a mouse model (Leng et al.. Oncogene 2008). Regarding Jak2, we show that it is part of a large signaling network (Samanta et al., Can Res., 2006). Inhibifion of Jak2 induces apoptosis in imatinib-sensitive/resistant Bcr-Abl + cells, in CML cell lines and in cells from blast crisis CML patients. Concerning Bcr, wild-type Bcr protein inhibits the oncogenic function of Bcr-Abl but serine/threonine kinase-defective Bcr enhances the oncogenic effects of Bcr-Abl (Perazzona et al.. Oncogene, 2008).
Aim #1, Develop a monoclonal anfibody that blocks lipocalin 2 (NGAL/24p3) activities induced by Bcr-Abl, and investigate the effects in mouse leukemia models. Our goal is to interfere with NGAL function for treatment of CML in combination with other therapeutic regimens such as Gleevec therapy.
Aim #2, Investigate the mechanistic effects of new Jak2 inhibitors in imatinib-sensitive and resistant CML cell lines, patient cells, and in patient cells from advanced stages of CML with the long-term goal of doing clinical trials in imafinib-resistant CML and late stage CML (with Dr. Cortes). We hypothesize that a potent Jak2 inhibitor will be useful in the treatment of drug-resistant CML as well as in all stages of CML because of the dominant role of Jak2 in oncogenic signaling in CML cells. We have identified a new Jak2 inhibitor (WP1193) that disrupts the Bcr-Abl/Jak2/HSP90 signaling network complex leading to apoptosis of drug-resistant CML cells and blast crisis CML cells. Surprisingly, preliminary results indicate that the Jak2 kinase phosphorylates Tyr 177 of Bcr-Abl, which upon Jak2 inhibifion drasfically reduced Grb2 binding to the network complex and caused the disruption of the Ras and PI-3 kinase signaling pathways. Importantly, Jak2 inhibition also drastically reduced Bcr-Abl protein levels, causing down-regulafion of STAT5 and STAT3 signaling. Thus, Jak2 inhibition disrupts many If not all oncogenic effects in CML.
Aim #3, Invesfigate the role ofthe Bcr Ser/Thr kinase in regulafing Bcr-Abl oncogenic activity. We will search for mutations in the Bcr kinase domain, as we hypothesize that such mutations play a role in CML disease progression.

Public Health Relevance

The outcome of these studies will lead to new strategies to treat drug-resistant forms of chronic myeloid leukemia and advanced stages of CML. Each strategy was based on published research generated by the Ariinghaus lab over the last five years of support from this P01 grant and a ROI grant from NIH.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Kanagal-Shamanna, Rashmi; Jain, Preetesh; Takahashi, Koichi et al. (2017) TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123:3717-3724
Jain, Preetesh; Burger, Jan A; Khoury, Joseph D (2017) CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation. Am J Hematol 92:1113-1114
Zhou, H; Mak, P Y; Mu, H et al. (2017) Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia 31:2065-2074
Peters, Haley L; Tripathi, Satyendra C; Kerros, Celine et al. (2017) Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 5:319-329
Andersson, B S; Thall, P F; Valdez, B C et al. (2017) Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52:580-587
Issa, Ghayas C; Kantarjian, Hagop M; Gonzalez, Graciela Nogueras et al. (2017) Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 130:2084-2091
Jain, Preetesh; Kantarjian, Hagop M; Ghorab, Ahmad et al. (2017) Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123:4391-4402
Raynal, Noël J-M; Da Costa, Elodie M; Lee, Justin T et al. (2017) Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Mol Cancer Ther 16:397-407
Ciurea, Stefan O; Schafer, Jolie R; Bassett, Roland et al. (2017) Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood 130:1857-1868
Jain, Preetesh; Kantarjian, Hagop; Jain, Nitin et al. (2017) Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol 92:E595-E597

Showing the most recent 10 out of 360 publications